Innovent Biologics Inc (6IB) — Financial Flexibility Index
Innovent Biologics Inc (6IB) has a Financial Flexibility Index of 0.00x as of June 2023. Free cash flow of €-12.49 Million (operating CF €-311.45 Million minus capex €298.95 Million) represents 0% of total liabilities (€7.11 Billion). Check cash flow reinvestment rate of Innovent Biologics Inc to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Innovent Biologics Inc Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Innovent Biologics Inc across 10 annual periods. For the full cash flow conversion analysis, see Innovent Biologics Inc operating cash flow efficiency.
Annual Financial Flexibility Index for Innovent Biologics Inc (2016–2025)
Year-by-year free cash flow to debt coverage for Innovent Biologics Inc. Explore cash flow to debt ratio of Innovent Biologics Inc to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.59x | €10.68 Billion | €10.00 Billion | €17.99 Billion | ▲ +68.4% |
| 2024 | 0.35x | €2.99 Billion | €1.29 Billion | €8.48 Billion | ▲ +86.6% |
| 2023 | 0.19x | €1.53 Billion | €147.81 Million | €8.10 Billion | ▲ +341.4% |
| 2022 | -0.08x | €-537.07 Million | €-1.92 Billion | €6.86 Billion | ▲ +51.7% |
| 2021 | -0.16x | €-959.21 Million | €-2.02 Billion | €5.91 Billion | ▼ -373.3% |
| 2020 | 0.06x | €181.33 Million | €-307.69 Million | €3.06 Billion | ▲ +111.3% |
| 2019 | -0.52x | €-1.30 Billion | €-1.66 Billion | €2.47 Billion | ▼ -44.0% |
| 2018 | -0.36x | €-699.09 Million | €-1.01 Billion | €1.92 Billion | ▼ -270.5% |
| 2017 | -0.10x | €-401.30 Million | €-492.27 Million | €4.08 Billion | ▼ -21.9% |
| 2016 | -0.08x | €-304.55 Million | €-362.99 Million | €3.77 Billion | — |